Psychiatric Side Effects of Meropenem (Ronem)
Meropenem can cause neuropsychiatric adverse effects including seizures, confusion, delirium, and rarely psychosis, though these occur in less than 1% of patients and are generally reversible upon drug discontinuation.
Key Psychiatric and Neurological Manifestations
The neuropsychiatric side effects associated with meropenem include 1:
- Seizures - The most clinically significant CNS effect, though meropenem has a notably lower propensity for inducing seizures compared to other carbapenems like imipenem 2, 3, 4
- Confusion and delirium
- Anxiety and depression
- Psychosis and mania (rare)
- Headaches
Clinical Context and Risk Factors
Meropenem is actually the carbapenem of choice when CNS penetration is needed because it demonstrates better CNS tolerability than imipenem 2, 3. In clinical trials of bacterial meningitis, no patients experienced seizures after starting meropenem therapy, even at high doses up to 6g/day 3.
Important Risk Considerations:
- Renal impairment increases risk of neurotoxicity due to drug accumulation
- Pre-existing CNS disorders may predispose to neuropsychiatric effects
- High cumulative doses increase risk
- The overall incidence of neurotoxicity with antimicrobials is estimated at <1% 1
Recent Pharmacovigilance Data
A 2026 analysis of the FDA Adverse Event Reporting System identified meropenem-associated adverse events across multiple organ systems 5. While the analysis focused primarily on hematologic and systemic effects, neuropsychiatric signals were detected with:
- Median time-to-onset of 5 days for adverse events
- Early-onset clustering pattern (Weibull β = 0.72)
- Higher reporting rates in patients aged 40-79 years
Clinical Management Algorithm
If psychiatric symptoms develop during meropenem therapy:
Immediately assess for:
- Renal function (creatinine clearance)
- Electrolyte abnormalities
- Concurrent medications that may lower seizure threshold
- Underlying CNS pathology
Discontinue meropenem - Most neurotoxic effects are reversible with drug withdrawal 1
Provide supportive care and monitor closely
Consider alternative antibiotics if continued therapy needed
Important Caveats
- The provided FDA drug label 6 appears to be for ondansetron (an antiemetic), not meropenem, and is therefore not applicable to this question
- Meropenem remains safer for CNS use than other carbapenems, making it the preferred agent when meningeal penetration is required 2, 3
- Dose adjustment is essential in renal impairment to prevent drug accumulation and neurotoxicity
- While psychiatric effects can occur, they are uncommon and typically resolve completely after discontinuation 1, 4